Estradiol
- Generic Name
- Estradiol
- Brand Names
- Activella 1/0.5 28 Day, Activelle, Amabelz 0.5/0.1 28 Day, Angeliq 0.25/0.5 28 Day, Bijuva, Climara, Climara Pro, Combipatch, Divigel, Dotti, Elestrin, Estalis, Estrace, Estradot, Estring, Estrogel, Etyqa 0.5/0.1 28 Day, Evamist, Imvexxy 4 Mcg Starter Pack, Lopreeza 1/0.5 28 Day, Lyllana, Menostar, Mimvey, Minivelle, Myfembree, Oesclim, Oriahnn 28 Day Kit, Prefest 30 Day, Vagifem, Vivelle, Yuvafem
- Drug Type
- Small Molecule
- Chemical Formula
- C18H24O2
- CAS Number
- 50-28-2
- Unique Ingredient Identifier
- 4TI98Z838E
- Background
Estradiol is a naturally occurring hormone circulating endogenously in females. It is commercially available in several hormone therapy products for managing conditions associated with reduced estrogen, such as vulvovaginal atrophy and hot flashes. Some available forms of estradiol include oral tablets, injections, vaginal rings, transdermal patches, sprays,...
- Indication
Estradiol is indicated in various preparations for the treatment of moderate to severe vasomotor symptoms and vulvar and vaginal atrophy due to menopause, for the treatment of hypoestrogenism due to hypogonadism, castration, or primary ovarian failure, and for the prevention of postmenopausal osteoporosis. It is also used for the treatment of breast cancer (...
- Associated Conditions
- Atrophic Vaginitis, Breast Cancer, Breast engorgement caused by Postpartum state, Heavy Menstrual Bleeding, Hypogonadism female, Kraurosis Vulvae, Metastatic Breast Cancer, Osteoporosis, Postmenopausal Osteoporosis, Premature Ovarian Failure (POF), Prostate Cancer, Severe Pain, Urogenital atrophy, Vasomotor Symptoms Associated With Menopause, Vulvo Vaginal Atrophy, Advanced androgen dependent Prostate cancer, Female castration, Hypoestrogenism
- Associated Therapies
- Contraception, Hormone Replacement Therapy, Palliative Treatment
The Effects of Resveratrol and Acute Exercise on Endothelial Function in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2014-10-03
- Last Posted Date
- 2020-03-20
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 25
- Registration Number
- NCT02256540
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Perimenopausal Effects of Estradiol on Reward Responsiveness
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- University of North Carolina, Chapel Hill
- Target Recruit Count
- 64
- Registration Number
- NCT02255175
- Locations
- 🇺🇸
University of North Carolina, Chapel Hill, North Carolina, United States
Estradiol Vaginal Softgel Capsules in Treating Symptoms of Vulvar and Vaginal Atrophy in Postmenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2014-10-01
- Last Posted Date
- 2017-05-25
- Lead Sponsor
- TherapeuticsMD
- Target Recruit Count
- 764
- Registration Number
- NCT02253173
- Locations
- 🇺🇸
Women's Clinic of Lincoln, Lincoln, Nebraska, United States
🇺🇸Chattanooga Medical Research, Chattanooga, Tennessee, United States
🇺🇸Medical Affiliated Research Center, Huntsville, Alabama, United States
A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers
- Conditions
- Interventions
- First Posted Date
- 2014-09-12
- Last Posted Date
- 2024-06-14
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 19
- Registration Number
- NCT02238808
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women
- Conditions
- Interventions
- First Posted Date
- 2014-04-24
- Last Posted Date
- 2022-01-10
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 17
- Registration Number
- NCT02122198
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
🇺🇸University of Colorado Boulder Intermountain Neuroimaging Consortium, Boulder, Colorado, United States
Sex Hormones and Atherosclerosis Prevention in Perimenopausal Women
- Conditions
- Interventions
- First Posted Date
- 2014-01-22
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 100
- Registration Number
- NCT02042196
- Locations
- 🇺🇸
University of Colorado Denver, Aurora, Colorado, United States
E2 and LDX for the Treatment of Cognitive Complaints After Oophorectomy
- Conditions
- Interventions
- First Posted Date
- 2013-11-18
- Last Posted Date
- 2017-03-24
- Lead Sponsor
- University of Pennsylvania
- Registration Number
- NCT01986764
- Locations
- 🇺🇸
Penn Center for Women's Behavioral Wellness, Philadelphia, Pennsylvania, United States
REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Polly A. Niravath, MD
- Target Recruit Count
- 44
- Registration Number
- NCT01984138
- Locations
- 🇺🇸
Houston Methodist Cancer Center, Houston, Texas, United States
A Safety and Efficacy Study of the Combination Estradiol and Progesterone to Treat Vasomotor Symptoms
- First Posted Date
- 2013-09-16
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- TherapeuticsMD
- Target Recruit Count
- 1845
- Registration Number
- NCT01942668
- Locations
- 🇺🇸
Accelovance, Melbourne, Florida, United States
🇺🇸Clinical Research of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Radiant Research (Chicago), Chicago, Illinois, United States
Estradiol Levels in Patients Treated With Estring
- First Posted Date
- 2013-08-15
- Last Posted Date
- 2022-02-10
- Lead Sponsor
- University of Arizona
- Target Recruit Count
- 14
- Registration Number
- NCT01923298
- Locations
- 🇺🇸
University of Arizona, Tucson, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.